Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics (AMEX:LCTX) is set to report its third quarter 2021 financial and operating results on November 10, 2021, after U.S. market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide business updates. Lineage specializes in allogeneic cell therapies targeting significant unmet medical needs, with three key product candidates in development for conditions such as dry age-related macular degeneration and acute spinal cord injuries, presenting billion-dollar market opportunities.
Lineage Cell Therapeutics (LCTX) announced updated interim results from its Phase 1/2a clinical study of OpRegen®, targeting dry age-related macular degeneration (AMD). The study presentation will occur at the 2021 American Academy of Ophthalmology meeting on November 13, 2021. OpRegen has shown ability to halt or reverse geographic atrophy and restore retinal tissue in three patients. The presentation will include data from 24 patients with a minimum 12-month follow-up, highlighting improved baseline vision in the latest cohort.
Lineage Cell Therapeutics (LCTX) announces participation in a fireside chat hosted by B. Riley Securities on 12:30 PM Eastern. The chat will feature company executives including Brian M. Culley and Kevin Cook, and will discuss ongoing cell therapy developments. Notably, the chat aims to highlight therapeutic advancements in treating conditions such as age-related macular degeneration and spinal cord injuries. Interested investors can register to attend the live event today.
Lineage Cell Therapeutics announced statistically significant interim results from its Phase 1/2a study of OpRegen for treating dry age-related macular degeneration (AMD). After 9 to 15 months of follow-up, patients receiving OpRegen showed improved visual acuity compared to untreated eyes, with p-values indicating significance (P = 0.0085 at 9 months). The therapy was well tolerated, with no new adverse effects reported. The results suggest potential for OpRegen to address unmet needs in AMD treatment.
Lineage Cell Therapeutics, a clinical-stage biotechnology firm focused on allogeneic cell therapies, announced that CEO Brian M. Culley will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 27 at 4pm ET. Interested parties can register for both live and on-demand presentations on the company's website. Lineage is developing three main products: OpRegen, OPC1, and VAC2, targeting significant health issues like dry age-related macular degeneration and non-small cell lung cancer.
Lineage Cell Therapeutics reported interim results from its Phase 1/2a study of OpRegen, a cell therapy for dry age-related macular degeneration (AMD). Key findings include:
- Zero growth of retinal atrophy in one patient after 33 months.
- 10% reduction in atrophy size noted at 8 months in another patient.
- Average visual acuity improvement of 10.8 letters in treated versus untreated eyes.
OpRegen has shown strong tolerability with no unexpected adverse events, suggesting potential for significant therapeutic outcomes.
Lineage Cell Therapeutics (LCTX) announced updated interim results from its Phase 1/2a study of OpRegen®, a cell therapy targeting dry age-related macular degeneration (AMD). The therapy aims to improve vision in patients with geographic atrophy. A podium presentation is scheduled for September 30, 2021, at the 54th Annual Scientific Meeting of the Retina Society in Chicago. The study includes a total of 24 patients, and the upcoming interim results will provide follow-up data for all treated patients, particularly focusing on Cohort 4, which showed better baseline vision.
Lineage Cell Therapeutics has appointed George A. Samuel III as its new General Counsel and Corporate Secretary. With nearly 15 years in corporate and transactional law, his background includes roles at Lytx and Cardiff Oncology, where he handled legal operations and compliance. The company anticipates Samuel's expertise will support its clinical development efforts and business partnerships, particularly for its OpRegen, OPC1, and VAC2 programs, which target significant medical needs and market opportunities.
Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 2021 results, highlighting significant advancements in its clinical programs, particularly OpRegen for dry-AMD. Notably, 83% of patients exhibited stable or improved visual acuity six months post-treatment. The company is also reacquiring OPC1 for clinical trials, aided by a robust cash position of $68.7 million. Total revenue increased to $0.5 million due to new licensing agreements, despite a net loss of $4.8 million. Lineage's inclusion in the Russell 3000® Index is expected to enhance visibility.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the H.C. Wainwright & Co. Inc. Virtual Ophthalmology Conference on August 17, 2021. The presentation will be available on-demand starting at 7am ET, and Mr. Culley will also join a panel discussion on addressing unmet medical needs in macular degeneration at 11am ET. Interested viewers can register for these presentations on the company's website, which also offers additional media resources.